Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.

Article  CAS  PubMed  Google Scholar 

Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, et al. FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR(+)) breast cancer. Clin Cancer Res. 2019;25:6443–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10:1373.

Article  PubMed  PubMed Central  Google Scholar 

Braun M, Piasecka D, Tomasik B, Mieczkowski K, Stawiski K, Zielinska A, et al. Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma. Cancers. 2020;12:2713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piasecka D, Kitowska K, Czaplinska D, Mieczkowski K, Mieszkowska M, Turczyk L, et al. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget. 2016;7:86011–25.

Article  PubMed  PubMed Central  Google Scholar 

Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, et al. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res. 2017;23:4323–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013;19:809–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

French DM, Lin BC, Wang M, Adams C, Shek T, Hotzel, K, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE. 2012;7(5):e36713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jomrich G, Hudec X, Harpain F, Winkler D, Timelthaler G, Mohr T, et al. Expression of FGF8, FGF18, and FGFR4 in gastroesophageal adenocarcinomas. Cells. 2019;8:1092.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: a promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther. 2020;214:107590.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen F, Zhang K, Wang M, He Z, Yu B, Wang X, et al. VEGF-FGF Signaling Activates Quiescent CD63(+) Liver Stem Cells to Proliferate and Differentiate. Adv Sci (Weinh). 2024;11:e2308711.

Article  PubMed  PubMed Central  Google Scholar 

Zhou L, Ou S, Liang T, Li M, Xiao P, Cheng J, et al. MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone-mediated autophagy. FEBS J. 2023;290:3614–28.

Article  CAS  PubMed  Google Scholar 

He WP, Yang GP, Yang ZX, Shen HW, You ZS, Yang GF. Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer. J Ovarian Res. 2022;15:55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meijer D, Sieuwerts AM, Look MP, van Agthoven T, Foekens JA, Dorssers LC. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer. 2008;15:101–11.

Article  CAS  PubMed  Google Scholar 

Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Invest. 2020;130:4871–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Servetto A, Formisano L, Arteaga CL. FGFR signaling and endocrine resistance in breast cancer: challenges for the clinical development of FGFR inhibitors. Biochim Biophys Acta Rev Cancer. 2021;1876:188595.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner KM, Yeo SK, Holm TM, Shaughnessy E, Guan JL. Heterogeneity within molecular subtypes of breast cancer. Am J Physiol Cell Physiol. 2021;321:C343-343C354.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13:227.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vignesh K, Thangamalar P. Regulatory role of lncRNA MALAT1 and miR-150-3p interaction in breast cancer progression and therapeutic implications. Cancer Plus. 2024;6:2633.

Article  Google Scholar 

Wu Y, Yi Z, Li J, Wei Y, Feng R, Liu J, et al. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts. Theranostics. 2022;12:4564–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braun M, Piasecka D, Sadej R, Romanska HM. FGFR4-driven plasticity in breast cancer progression and resistance to therapy. Br J Cancer. 2024;131:11–22.

Article  PubMed  PubMed Central  Google Scholar 

Liu X, Zhang G, Zhao L. Detection of transmembrane protein 100 in breast cancer: correlation with malignant progression and chemosensitivity. Cytojournal. 2024;21:65.

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Zhang Y, Cao J, Su Z, Li F, Zhang P, et al. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. J Exp Clin Cancer Res. 2023;42:96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lukas L, Ri Han H, T. Roussos Torres E, G. Baugh A, Bell O, C. Ye J, et al. Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative breast cancer. Advances in Radiotherapy & Nuclear Medicine. 2025;3:28.

Article  CAS  Google Scholar 

Zhao C, Song W, Wang J, Tang X, Jiang Z. Immunoadjuvant-functionalized metal-organic frameworks: synthesis and applications in tumor immune modulation. Chem Commun (Camb). 2025;61:1962–77.

Article  CAS  PubMed  Google Scholar 

You W, Zhou Z, Li Z, Yan J, Wang Y. From foe to friend: rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor. J Pharm Anal. 2025;15:101322.

Article  PubMed  PubMed Central  Google Scholar 

Yuan H, Chen Y, Hu Y, Li Y, Zhang H, Zhang S, et al. Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy. J Pharm Investig. 2025;55:889–902.

Article  CAS  Google Scholar 

Kaplan HM, Mete S. Haplophyllum buxbaumii induces apoptosis via MAPK and AKT/mTOR pathways in MCF-7 breast cancer cell line. Int J Pharmacol. 2023;19:531–6.

Article  CAS  Google Scholar